The Grumpy Doc

Grumpy opinions about everything.

Category: Medicine Page 2 of 7

Of course there will be medicine. I am The Grumpy Doc.

Fecal Microbiota Transplantation: When Waste Becomes Therapy

By

On February 4, 2026

In Medicine

Today I’m going to talk about something that may sound unbelievable and maybe even a little gross—fecal transplant. Yes, it’s exactly what it sounds like. Getting a transplant of someone else’s poop.

The human gut contains trillions of microorganisms—bacteria, viruses, fungi—living in a complex ecosystem that influences everything from digestion to immune function. This is called the microbiome.  When this ecosystem gets disrupted, the consequences can range from uncomfortable to life-threatening. Enter one of medicine’s most counterintuitive treatments: fecal microbiota transplantation, or FMT, where stool from a healthy donor is transferred to a patient to restore a healthy community of gut microbes.

What Is FMT

The basic idea is simple: if someone’s microbiome has been badly disrupted (most commonly by repeated antibiotic exposure), replacing it with a balanced microbial ecosystem can help the gut recover.  At its core, FMT is taking fecal matter from a healthy donor and introducing it into a patient’s gastrointestinal tract. But it’s not the solid waste itself that matters; it’s the billions of beneficial bacteria and other microorganisms living in that material. Think of it as a probiotic treatment on steroids, delivering an entire functioning ecosystem rather than just a few select bacterial strains.

The gut microbiome plays crucial roles in digestion, vitamin production, immune system regulation, and even protection against harmful pathogens. When antibiotics, illness, or other factors devastate this ecosystem, dangerous bacteria like Clostridioides difficile (C. diff) can take over, causing severe diarrhea, inflammation, and potentially fatal infections.

The Clinical Track Record

While it may sound like “weird science”, FMT has been around for centuries. It was used in ancient Chinese medicine in a formulation called “yellow soup“ to treat food poisoning and intractable diarrhea. It was used as early as the 16th century in Europe to treat sick farm animals, particularly sheep and cattle.

FMT’s most dramatic success story involves C. diff infections, particularly the recurrent cases that don’t respond to antibiotics. Multiple randomized controlled trials have shown FMT to be remarkably effective—with cure rates often exceeding 80-90% for recurrent C. diff infections, compared to roughly 25-30% for continued antibiotic therapy. A landmark 2013 study reported in the New England Journal of Medicine was stopped early because FMT was so dramatically superior to standard treatment that continuing to withhold it from the control group seemed unethical.

Beyond C. diff, researchers are investigating FMT for inflammatory bowel diseases like ulcerative colitis and Crohn’s disease, with mixed but occasionally promising results. Some studies have shown potential for ulcerative colitis, with remission rates around 24-27%. The research into Crohn’s disease, irritable bowel syndrome, metabolic disorders, and even neurological conditions is ongoing but less conclusive. The FDA currently considers FMT an investigational treatment for most conditions except recurrent C. diff, where it’s become a recognized therapeutic option.

How It Works

The actual process of FMT can use several routes. The most common approaches involve colonoscopy, where the donated material is delivered directly to the colon, or through nasogastric or nasoduodenal tubes that thread through the nose down to the small intestine. More recently, oral capsules containing frozen, encapsulated donor stool have become available, offering a less invasive alternative that patients often prefer.

Before the transplant, the donated stool is carefully processed. It’s typically mixed with a saline solution and filtered to remove large particles while preserving the microbial communities. The resulting liquid suspension is what gets delivered to the patient. For frozen preparations, this material is mixed with a cryoprotectant, frozen at extremely cold temperatures, and can be stored for months before use.

The preparation isn’t just about the donor material—patients often undergo their own preparation. Many protocols include antibiotics to reduce the overgrowth of harmful bacteria before the transplant, followed by bowel cleansing similar to what you’d do before a colonoscopy. The idea is to create a relatively clean slate where the new microbial ecosystem can establish itself.

Sources of Donor Material

This brings us to one of the most critical aspects: donor selection and screening. Not just anyone can donate stool for medical use. The screening process is extensive and rigorous, rivaling or exceeding the scrutiny applied to blood donation.

Donors undergo detailed health questionnaires covering everything from recent travel and antibiotic use to gastrointestinal symptoms and risk factors for infectious diseases. They provide blood and stool samples that are tested for a long list of potential pathogens: C. diff, Helicobacter pylori, parasites, hepatitis A, B, and C, HIV, syphilis, and various other bacteria and viruses. The FDA issued guidance requiring additional testing for multi-drug resistant organisms after several patients contracted serious infections from FMT.

Donors generally fall into two categories: directed donors and universal donors. Directed donors are typically family members or friends who undergo screening and provide stool specifically for one patient. Universal donors go through the same rigorous screening but provide samples that can be used for multiple patients. These universal donors often work with stool banks—specialized facilities that collect, process, screen, and distribute donor material to healthcare providers.

The largest stool bank in the United States, OpenBiome, was founded in 2012 and has processed material from thousands of donors for tens of thousands of treatments. They report that only about 2-3% of volunteer donors successfully make it through the screening process, highlighting just how selective the criteria are. These banks have made FMT more widely available, eliminating the need for individual healthcare facilities to find and screen their own donors.

The Balance of Promise and Caution

While FMT represents a genuine breakthrough for recurrent C. diff infections, the medical community remains appropriately cautious about expanding its use. The FDA regulates FMT and has expressed concerns about potential risks, particularly after cases where patients developed serious infections from inadequately screened donors. There questions about the long-term effects of introducing another person’s microbiome, and there are theoretical concerns about transmitting conditions or predispositions we don’t fully understand.

The research into FMT for conditions beyond C. diff continues, but many trials have shown modest or inconsistent results. The microbiome’s role in health and disease is incredibly complex, and what works dramatically for one condition may not translate to others. Still, the fundamental insight—that our gut microbiome profoundly influences our health and that we can therapeutically manipulate it—has opened potential new avenues in medicine.

Sources

                1. van Nood, E., et al. (2013). “Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile.” New England Journal of Medicine, 368(5), 407-415. https://www.nejm.org/doi/full/10.1056/NEJMoa1205037

                2. U.S. Food and Drug Administration. “Fecal Microbiota for Transplantation: Safety Information.” https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fecal-microbiota-transplantation-safety-information

                3. Cammarota, G., et al. (2017). “European consensus conference on faecal microbiota transplantation in clinical practice.” Gut, 66(4), 569-580. https://gut.bmj.com/content/66/4/569

                4. Moayyedi, P., et al. (2015). “Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.” Gastroenterology, 149(1), 102-109. https://www.gastrojournal.org/article/S0016-5085(15)00381-5/fulltext

                5. Kelly, C.R., et al. (2016). “Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook.” Gastroenterology, 150(1), 276-290. https://www.gastrojournal.org/article/S0016-5085(15)01626-7/fulltext

                6. OpenBiome. “Our Process: Screening.” https://www.openbiome.org/safety

                7. Quraishi, M.N., et al. (2017). “Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection.” Alimentary Pharmacology & Therapeutics, 46(5), 479-493. https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14201​​​​​​​​​​​​​​​​

Illustration generated by author using Midjourney

The Price Tag Mystery: Why Nobody Really Knows What Healthcare Costs in America

By

On January 29, 2026

In Commentary, Medicine, Politics

Imagine walking into a store where nothing has a price tag. When you get to the register, the cashier scans your items and tells you the total—but that total is different for every customer. Your neighbor might pay $50 for the same items that cost you $200. The store won’t tell you why, and you won’t find out until after you’ve already “bought” everything.

Welcome to American healthcare, where the simple question “how much does this cost?” has no simple answer.

You might think I’m exaggerating, but the evidence suggests otherwise. Research published in late 2023 by PatientRightsAdvocate.org found that prices for the same medical procedure can vary by more than 10 times within a single hospital depending on which insurance plan you have, and by as much as 33 times across different hospitals. A knee replacement that costs around $23,170 in Baltimore might run $58,193 in New York. An emergency department visit that one facility charges $486 for might cost $3,549 at another hospital for the identical service.

The fundamental problem is that hospitals and doctors don’t have one price for their services. They have dozens, sometimes hundreds, of different prices for the exact same procedure depending on who’s paying. This bizarre system evolved because most healthcare in America isn’t a simple transaction between patient and provider—there’s a third party in the middle called an insurance company, and that changes everything.

The Fiction of Chargemaster Prices

A hospital chargemaster is essentially the hospital’s internal price list—a massive catalog that assigns a dollar amount to every service, supply, test, medication, and procedure the hospital can bill for, from an aspirin to a complex surgery. These listed prices are usually very high and are not what most patients actually pay; instead, the chargemaster functions as a starting point for negotiations with insurers and government programs like Medicare and Medicaid, which typically pay much lower, pre-set rates. What an individual patient ultimately pays depends on several factors layered on top of the chargemaster price. Think of them like the manufacturer’s suggested retail price on a car: technically real, but nobody pays them.

A hospital might list an MRI at $3,000 or a blood test at $500. But then insurance companies come in. They represent thousands or millions of potential patients, which gives them serious bargaining power. They negotiate with hospitals along these lines: “We’ll send you lots of patients, but only if you give us a discount.” So, the hospital agrees to accept much less—maybe they’ll take $1,200 for that $3,000 MRI or $150 for the blood test. This discounted amount is called the “negotiated rate,” and it’s what the insurance company will really pay.

Here’s where it gets messy: every insurance company negotiates its own rates with every hospital. Blue Cross might negotiate one price, Aetna a different price, UnitedHealthcare yet another. The same exact MRI at the same hospital might be $1,200 for one insurer’s customers and $1,800 for another’s. And these negotiated rates have traditionally been kept secret—treated like confidential business information that gives each party a competitive advantage.

The Write-Off Game

What happens to that difference between the chargemaster price and the negotiated rate? The hospital “writes it off.” That’s accounting language for “we accept that we’re not getting paid this money, and we’re taking it off the books.” If the hospital charged $3,000 but agreed to accept $1,200, they write off $1,800. This isn’t lost money in the normal sense—they never expected to collect it in the first place. The chargemaster prices are inflated specifically because everyone knows discounts are coming. Some hospitals now post “discounted cash prices” that are often far below chargemaster and sometimes even below some negotiated rates. These are sometimes, though not always, offered to uninsured patients, generally referred to as self-pay. There can be a catch—some hospitals require lump-sum payment of the total bill to qualify for the lower price.

According to the American Hospital Association, U.S. hospitals collectively plan to write off approximately $760 billion in billed charges in 2025 across all categories of write-offs. That’s not a typo—$760 billion. These write-offs happen in several different situations. The most common are contractual write-offs, where the provider has agreed to accept less than their list price from insurance companies.

Hospitals have far more write-offs than just contractual.  They also write off money for charity care—treating patients who can’t afford to pay anything, and they write off bad debt when patients could pay but don’t. They write off small balances that aren’t worth the administrative cost of collection, and they write off amounts related to various billing errors, denied claims, and coverage disputes. Healthcare providers typically adjust about 10 to 12 percent of their gross revenue due to these various write-offs and claim adjustments.

Why Such Wild Variation?

Even with all these negotiated discounts built into the system, the prices still vary enormously. A 2024 study from the Baker Institute found that for emergency department visits, the price charged by hospitals in the top 10% can be three to seven times higher than the hospitals in the bottom 10% for the identical procedure. Research published in Health Affairs Scholar in early 2025 found that even after adjusting for differences between insurers and procedures, the top 25% of prices across all states is 48 percent higher than the bottom 25% of prices for inpatient services.

Several factors drive this variation. Hospitals in areas with less competition can charge more because insurers have fewer alternatives for negotiation. Prestigious hospitals can demand higher rates because insurers want them in their networks to attract customers. Some insurance companies have more bargaining power than others based on their market share. There’s no central authority setting prices—it’s all private negotiations, hospital by hospital, insurer by insurer, procedure by procedure.

For patients, this creates a nightmare scenario. Even if you have insurance, you usually have no idea what you’ll pay until after you’ve received care. Your out-of-pocket costs depend on your deductible (the amount you pay before insurance kicks in), your copay or coinsurance (your share after insurance starts paying), and whether the negotiated rate between your specific insurance and that specific hospital is high or low. Two people with different insurance plans getting the same procedure at the same hospital on the same day can end up with drastically different bills.

Research using new transparency data confirms this isn’t just anecdotal. A study from early 2025 found that for something as routine as a common office visit, mean prices ranged from $82 with Aetna to $115 with UnitedHealth. Within individual insurance companies, the price of the top 25% of office visits was 20 to 50 percent higher than the bottom 25%, meaning even within one insurer’s network, where you go or where you live makes a huge difference.

The Government Steps In

The federal government finally said “enough” and started requiring transparency. Since 2021, hospitals must post their prices online, including what they’ve negotiated with each insurance company. The Centers for Medicare and Medicaid Services (CMS) strengthened these requirements in 2024, mandating standardized formats and increasing enforcement. Health insurance plans face similar requirements to disclose their negotiated rates.

The theory was straightforward: if patients could see prices ahead of time, they could shop around, which would force prices down through competition. CMS estimated this could save as much as $80 billion by 2025. The idea seemed sound—transparency works in other markets, so why not healthcare?

In practice, it’s been messy. A Government Accountability Office (GAO) report from October 2024 found that while hospitals are posting data, stakeholders like health plans and employers have raised serious concerns about data quality. They’ve encountered inconsistent file formats, extremely complex pricing structures, and data that appears to be incomplete or possibly inaccurate. Even when hospitals post the required information, it’s often so convoluted that comparing prices across facilities becomes nearly impossible for average consumers.

An Office of Inspector General report from November 2024 found that not all selected hospitals were complying with the transparency requirements in the first place. And CMS still doesn’t have robust mechanisms to verify whether the data being posted is accurate and complete. The GAO recommended that CMS assess whether hospital pricing data are sufficiently complete and accurate to be usable, and to assess if additional enforcement if needed.

Imagine trying to comparison shop when one store lists prices in dollars, another in euros, and a third uses a proprietary currency they invented. That’s roughly where we are with healthcare price data—technically available, but practically unusable for most people trying to make informed decisions.

The Trump administration in 2025 signed a new executive order aimed at strengthening enforcement of price transparency rules and directing agencies to standardize and make hospital and insurer pricing information more accessible; this action built on rather than reduced the earlier requirements.  Hopefully this will improve the ability of patients to access real costs, but it is my opinion that the industry will continue to resist full and open compliance.

The Limits of Shopping for Healthcare

There’s also a deeper philosophical problem: for healthcare to work like a normal market where price transparency drives competition, patients would need to be able to shop around based on price. That could work for scheduled procedures like knee replacements, colonoscopies, or elective surgeries. You have time to research, compare, and choose.

But it doesn’t work at all when you’re having a heart attack, or your child breaks their arm. You go to the nearest hospital, period. You’re not calling around asking about prices while someone’s having a medical emergency. Even for non-emergencies, choosing based on price assumes equal quality across providers, which isn’t always true and is even harder to assess than price itself.

A study on price transparency tools found mixed results on whether they truly reduce spending. Some research shows modest savings when people use price comparison tools for shoppable services like imaging and lab work. But utilization of these tools remains low, and for many healthcare encounters, price shopping simply isn’t practical or appropriate.

Who Really Knows?

So, who truly understands what things cost in this system? Hospital administrators know what different insurers pay them for specific procedures, but that knowledge is limited to their facility. They don’t necessarily know what other hospitals charge. Insurance company executives know what they’ve negotiated with various hospitals in their network, but they haven’t historically shared meaningful price information with their customers in advance. And they don’t know what their competitors have negotiated.

Patients, caught in the middle, often find out their costs only when they receive a bill weeks after treatment. By that point, the care has been delivered, and the financial damage is done. Recent surveys suggest that surprise medical bills remain a significant problem, with many patients receiving unexpected charges from out-of-network providers they didn’t choose or even know were involved in their care.

The people who are starting to get a comprehensive view are researchers and policymakers analyzing the newly available transparency data. Studies published in 2024 and 2025 using these data have given us unprecedented visibility into pricing patterns and variation. But this is aggregate, statistical knowledge—it helps us understand the system but doesn’t necessarily help individual patients figure out what they’ll pay for a specific procedure.

Where We Stand

The transparency regulations represent a genuine attempt to inject some market discipline into healthcare pricing. Making negotiated rates public breaks down the information asymmetry that has allowed prices to vary so wildly. In theory, if patients and employers can see that Hospital A charges twice what Hospital B does for the same procedure, competitive pressure should push prices toward the lower end.

There’s some early evidence this might be working. A study of children’s hospitals found that price variation for common imaging procedures decreased by about 19 percent between 2023 and 2024, though overall prices continued rising. Whether this trend will continue and expand to other types of facilities remains to be seen.  I am concerned that rather than lowering overall prices it may cause hospitals at the lower end to raise their prices closer to those at the higher end.

Significant obstacles remain. The data quality issues need resolution before the information becomes truly usable. Many patients lack either the time, expertise, or practical ability to shop based on price. And the fundamental structure of American healthcare—with its complex interplay of providers, insurers, pharmacy benefit managers, and government programs—means that even perfect price transparency won’t create a simple, straightforward market.

So, to return to the original question: does anyone truly know the cost of medical care in the United States? In an aggregate sense, researchers and policymakers are starting to understand the patterns thanks to transparency requirements. The data are revealing just how variable and opaque pricing has been. But as a practical matter for individual patients trying to figure out what they’ll pay for needed care, not really. The information is becoming available but remains largely inaccessible or incomprehensible for ordinary people trying to make informed healthcare decisions.

The $760 billion in annual write-offs tells you everything you need to know: the posted prices are largely fictional, the negotiated prices vary wildly, and the system has evolved to be so complex that even the people operating within it struggle to understand the full picture. We’re making progress toward transparency, but we’re a long way from a healthcare system where patients can confidently get the answer to the simple question: “How much will this cost?”

A closing thought: All of this could be solved by development of a single-payer healthcare system such as I proposed in my previous post America’s Healthcare Paradox: Why We Pay Double and Get Less.

Hepatitis B Vaccine: Three Shots and You’re Done for Life?

By

On January 28, 2026

In Medicine

If you’re trying to figure out whether you need a hepatitis B vaccine or wondering if the one you got years ago is still protecting you, you’re not alone. The hepatitis B vaccine is one of those medical interventions that raises straightforward questions: How many shots do you need? And does it really last forever?  I thought I should follow up last week’s general discussion of hepatitis with some specifics on this vaccine.

The Shot Schedule

The traditional hepatitis B vaccine series requires three shots spaced over six months. You get the first dose, then return for a second shot one to two months later and finally complete the series with a third dose at the six-month mark.  There is also a combination hepatitis A and B vaccine that follows the same schedule. This schedule has been the standard for decades and works well for both children and adults.

But here’s something newer: In 2017, the FDA approved a two-dose hepatitis B vaccine called Heplisav-B for adults 18 and older. With this option, you only need two shots spaced one month apart. For parents of young children, there is Pediarix, a combination vaccine that bundles hepatitis B protection with vaccines for other diseases, streamlining the infant immunization schedule.

Does It Really Last a Lifetime?

This is where the science gets interesting. The short answer is yes, for most people the protection appears to be lifelong. But the mechanism behind this is more nuanced than you might expect.

After you complete the vaccine series, your body produces antibodies against hepatitis B. Over time—sometimes after just a few years—the level of these antibodies in your blood can decline to the point where they’re barely detectable or even undetectable. On the surface, that sounds concerning. But here’s the key: your immune system has memory.

Even when antibody levels drop, your body retains specialized immune cells that “remember” hepatitis B. If you encounter the virus years or decades later, these memory cells spring into action, rapidly producing new antibodies to fight off the infection before it can establish itself. Researchers have followed vaccinated individuals for more than 30 years and found that this immune memory remains protective even when blood tests show low antibody levels.

Who Might Need a Booster?

For most people with healthy immune systems, the CDC doesn’t recommend booster shots. Once you’ve completed the series and your body has responded appropriately, you’re considered protected. However, there are exceptions. People with compromised immune systems—such as those undergoing dialysis, living with HIV, or taking immunosuppressive medications—may need periodic booster doses. These individuals should work with their healthcare providers to monitor their antibody levels and determine if additional shots are necessary.

The Bottom Line

The hepatitis B vaccine is a three-shot series (or two shots with the newer formulation) that provides protection that researchers believe lasts a lifetime for most people. While your antibody levels might decline over the years, your immune system’s memory keeps you safe. It’s one of those rare cases where you can check something off your health to-do list and genuinely move on.

Sources:

Understanding Hepatitis: A Guide to Types A, B, and C

By

On January 21, 2026

In Medicine

If you’ve heard of hepatitis, you probably know it has something to do with the liver. But there’s a whole family of hepatitis viruses, each with its own personality when it comes to how it spreads, what it does to your body, and how we can prevent or treat it. Let’s walk through the three most common types—hepatitis A, B, and C—and then dive into a controversy that’s making headlines right now: the hepatitis B vaccine.

What Is Hepatitis, Anyway?

At its core, hepatitis just means inflammation of the liver. Your liver is a workhorse organ that filters toxins, produces essential proteins like albumin, processes amino acids, and stores energy. When a hepatitis virus attacks it, the inflammation can range from a minor inconvenience to a life-threatening condition. The three main culprits—hepatitis A, B, and C viruses—are completely different organisms that just happen to target the same organ.

Hepatitis A: The Food and Water Troublemaker

Hepatitis A is often called “traveler’s hepatitis” because it spreads through food and water that are contaminated with fecal matter. Think of it as the virus you might pick up from eating unwashed produce, drinking contaminated water, or consuming raw shellfish from polluted waters. Other risk factors include unprotected sex and IV drug use.  According to the CDC, there were an estimated 3,300 acute infections in 2023 in the United States.

The good news about hepatitis A is that it typically heals itself within 2 months. When symptoms appear—which take about 15 to 50 days after infection—they can include jaundice (that yellowing of the skin and eyes), fever, fatigue, nausea, and dark urine. Many young children don’t show any symptoms at all. The virus doesn’t become chronic, and once you’ve had it, your body produces antibodies that protect you for life.

Prevention is straightforward: there’s a safe and effective vaccine, and basic hygiene goes a long way. Wash your hands thoroughly, especially after using the bathroom and before preparing food. When traveling to areas with questionable water quality, stick to bottled or boiled water and avoid washing raw food in local water.

Treatment is mostly supportive—rest, fluids, and time. Your liver does the healing work itself.

Hepatitis B: The Blood and Body Fluid Virus

Hepatitis B is where things get more serious. This virus spreads through blood and other body fluids, which means it can be transmitted through sexual contact, sharing needles, or from mother to baby during childbirth. Healthcare workers are especially at risk from needle sticks and sharps injuries. It’s a highly infectious and tough virus that can live on surfaces for up to a week. Even tiny amounts of dried blood on seemingly innocent things like razors, nail clippers, or toothbrushes can potentially spread the infection.

According to the CDC, there were an estimated 14,400 acute infections in 2023, Approximately 640,000 adults were living with chronic hepatitis B during the 2017-2020 period and that’s what makes it particularly concerning: while the hepatitis B virus often causes short-term illness, it can become chronic.

The incubation period is long—typically 90 days with a range of 60 to 150 days. When symptoms do appear, they mirror hepatitis A: jaundice, fatigue, abdominal pain, nausea, and dark urine. But here’s the frightening part: most young children and many adults show no symptoms at all, meaning they can spread the virus without knowing they’re infected.

The chronic infection risk varies dramatically by age. If you’re infected as a newborn, you have a 90% chance of developing chronic hepatitis B. For adults, the risk drops to under 5%. Those with chronic infection face serious long-term consequences—15% to 25% of people with chronic infection develop serious liver disease, including cirrhosis, liver failure, or liver cancer.

Treatment for acute hepatitis B is supportive, but several antiviral medications are available for people with chronic infection. These don’t completely eradicate the disease but produce a “functional cure” that significantly slows liver damage and reduces complications.

Prevention is critical. There’s a highly effective vaccine—we’ll talk more about the controversy surrounding it in a moment.  Avoiding exposure to infected blood and body fluids is essential. This means safe sex practices, never sharing needles or personal care items that might have blood on them, and ensuring proper sterilization of medical and tattooing equipment.

Hepatitis C: The Silent Epidemic

Hepatitis C is transmitted primarily through blood-to-blood contact. The most common route is sharing needles among people who inject drugs, though it can also spread through contaminated medical equipment, and rarely through sexual contact. Mother-to-child transmission during childbirth is possible but uncommon.  Screening of blood products has made transfusion related infections rare.  About 10% of cases have no identified source.

What makes hepatitis C insidious is its stealthy nature. Many people with hepatitis C don’t have symptoms, and acute hepatitis with jaundice is rare, occurring in only about 10% of infections. The symptoms that do appear—fatigue, mild flu-like feelings—are easily dismissed. Meanwhile, the majority of people (60-70%) develop chronic infection.  I recommend a screening blood test at least once for all adults over age 55, as they are the group most likely to have hepatitis C without an identifiable source.

The incubation period ranges widely, from 2 weeks to 6 months, typically 6 to 9 weeks. Without treatment, chronic hepatitis C can lead to cirrhosis and liver cancer over decades. Before modern treatments, it was a leading cause of liver transplants.

Treatment for hepatitis C has undergone a revolution. The old approach—interferon injections combined with ribavirin—had terrible side effects and worked in only about half of patients. Today, we have direct-acting antivirals (DAAs), which can cure more than 95% of cases with just 8-12 weeks of well-tolerated oral medication. These drugs target specific proteins the virus needs to replicate, essentially starving it out of existence. The treatment is so effective that hepatitis C is now considered a curable disease.

Prevention focuses on avoiding blood-to-blood contact. Never share needles, syringes, or any drug equipment. If you’re getting a tattoo or piercing, ensure the facility follows proper sterilization procedures. Healthcare workers should follow standard precautions with blood and body fluids. Unfortunately, there’s no vaccine for hepatitis C yet, though researchers continue working on one.

The Hepatitis B Vaccine Controversy: What’s Really Happening

Now let’s address the elephant in the room—the recent controversy over the hepatitis B vaccine for newborns. This topic exploded in the news in December 2025, and it’s worth understanding what’s currently going on versus what the science says.

The Recent Development

On December 5, 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted 8-3 to recommend hepatitis B vaccination at birth only for infants born to mothers who test positive for the virus or whose status is unknown. This reverses decades of policy that recommended universal hepatitis B vaccination for all newborns within 24 hours of birth.

The Arguments For Changing the Policy

Some ACIP members raised concerns about vaccine safety and parental hesitancy. Committee member Retsef Levi heralded the move as “a fundamental change in the approach to this vaccine,” which would encourage parents to “carefully think about whether they want to take the risk of giving another vaccine to their child”. The controversy includes historical concerns about possible links between the hepatitis B vaccine and conditions like multiple sclerosis, autism, and other autoimmune disorders.

What Science Actually Shows

The evidence on vaccine safety is quite robust.  Concerns about multiple sclerosis emerged in France in the 1990s. Since then, a large body of scientific evidence shows that hepatitis B vaccination does not cause or worsen MS. The World Health Organization’s Global Advisory Committee on Vaccine Safety has concluded there is no association between the hepatitis B vaccine and MS.  It is one of the safest vaccines studied.

As for other safety concerns, CDC reviewed VAERS reports from 2005-2015 and found no new or unexpected safety concerns. The most common side effects are minor: soreness at the injection site, headache, and fatigue lasting 1-2 days.

Why the Universal Birth Dose Matters

The scientific and medical communities have strongly opposed this policy change. The American Academy of Pediatrics states that from 2011-2019, rates of reported acute hepatitis B remained low among children and adolescents, likely explained in part by the implementation of childhood hepatitis B vaccine recommendations published in 1991.

Here’s why newborns are so vulnerable: infected infants have a 90% chance of developing chronic hepatitis B, and a quarter of those will die prematurely from liver disease when they become adults.

The “just target high-risk babies” approach has a major flaw: the CDC estimates about 640,000 adults have chronic hepatitis B, but about half don’t know they’re infected. Before universal vaccination, about half of infected children under 10 got it from their mothers—the rest contracted it through other exposures not identified by maternal screening.

The Global Context

Claims that the U.S. is an outlier don’t hold up. As of September 2025, 116 of 194 WHO member states recommend universal hepatitis B birth dose vaccination.  European countries that do not recommend a universal birth dose have a much lower hepatitis B incidence rate and more robust antenatal maternal screening.  The majority still recommend vaccination at two to three months.

The Bottom Line

All three types of hepatitis pose serious health risks, but we have powerful tools to prevent and treat them. Hepatitis A and B have safe, effective vaccines that have dramatically reduced disease rates. Hepatitis C, while lacking a vaccine, is now curable with modern antiviral medications.

The hepatitis B vaccine controversy highlights a broader tension in public health: balancing individual autonomy with community protection. The scientific evidence strongly supports the vaccine’s safety and the effectiveness of universal newborn vaccination in preventing a disease that can be fatal. Multiple studies, decades of safety data, and recommendations from medical organizations worldwide back this up.

For parents making decisions about their newborns, the facts are these: hepatitis B is a serious disease with a high risk of becoming chronic in infants, the vaccine is highly effective at preventing infection, and extensive safety monitoring has found it to be safe with only minor, temporary side effects. As hepatitis research continues, we’re seeing remarkable progress—from the near-eradication of hepatitis A in vaccinated populations to the transformation of hepatitis C from a chronic, often fatal disease to a curable one. These advances remind us how far we’ve come in understanding and combating these liver viruses.

Sources

Understanding Dementia: A Journey Through Memory Loss

By

On January 8, 2026

In Medicine

When someone tells you they’re having trouble remembering where they put their keys, that’s probably just normal aging. But when they forget what keys are for altogether, that’s when doctors start thinking about dementia. It’s a distinction that matters deeply to millions of families navigating one of medicine’s most challenging conditions.

While reviewing some of my previous articles, I realized that while I have discussed conditions that mimic dementia, I haven’t discussed dementia itself.  This discussion has quite a bit of technical jargon, but it’s unavoidable.

Dementia isn’t a specific disease—it’s an umbrella term describing a decline in mental ability that interferes with daily life. Think of it like how “cancer” describes many different diseases. About 50 percent of people age 85 and older have some form of dementia, making it one of the most pressing health challenges of our aging population.

The Major Players: Types of Dementia

Alzheimer’s Disease stands as the heavyweight champion of dementia causes, accounting for an estimated 50 to 70 percent of all cases. What’s happening in the brain is both complicated and tragic. Beta-amyloid and phosphorylated tau proteins accumulate and spread through distributed neural networks in the brain, causing progressive metabolic abnormalities, neuronal injury, and cellular death all of which disrupt functional connectivity. The hallmark symptoms include problems with short-term memory: paying bills, preparing meals, remembering appointments, or getting lost in familiar areas. Your grandmother might remember vivid details from her childhood but can’t recall what she ate for breakfast or even recognize you.

Vascular Dementia comes in second place, accounting for about 5 to 15 percent of cases. Typical symptoms include slowed thinking, trouble with organization, difficulty planning or following instructions, and in the later phases, gait problems and urinary difficulties.  It results from strokes or other problems with blood flow to the brain.  On occasion it may be the result of a series of subclinical strokes with the victim being unaware of the individual events.  Symptoms gradually become worse as blood vessels get damaged. Imagine the brain like a city—when the roads get blocked, supplies can’t get through, and neighborhoods start to fail.

Lewy Body Dementia Involves the deposit of abnormal alpha-synuclein proteins called Lewy bodies.  It presents a particularly unsettling picture. Many people with this type of dementia experience daytime sleepiness, confusion, fluctuating cognition, staring spells, sleep disturbances, visual hallucinations, or movement problems. The visual hallucinations are generally vivid images of people or animals and often occur when someone is about to fall asleep or wake up.

Frontotemporal Dementia often hits younger people. It is caused by abnormalities in the proteins FUS and TDP-43. Most cases are diagnosed in people aged 45 to 65. Rather than starting with memory loss, early symptoms may include personality changes like reduced sensitivity to others’ feelings, lack of social awareness, making inappropriate jokes, language problems, obsessive behavior, or sudden outbursts of anger. It’s heartbreaking when someone’s personality fundamentally changes before your eyes.

LATE is a newly recognized form of dementia (Limbic-predominant Age-related TDP-43 Encephalopathy), which causes symptoms similar to Alzheimer’s but has different underlying causes involving abnormal clusters of TDP-43 protein. Research suggests that almost 40 percent of people whose age at death was 88 years or greater may have had LATE of varying degrees.

Less Common Forms:  Parkinson’s disease dementia (movement disorder first, dementia later).Normal Pressure Hydrocephalus (NPH)—one of the few reversible types.  Chronic traumatic encephalopathy (CTE)—linked to repeated head injuries.HIV-associated dementia—less common with modern treatment.  Severe vitamin deficiencies (e.g., B1 or B12)—reversible if caught early.

Figuring Out What’s Wrong: The Diagnostic Process

Making a dementia diagnosis isn’t like getting a strep test or an Xray—there’s no single definitive test. Physicians use diagnostic tools combined with medical history and other information, including neurological exams, cognitive and functional assessments, brain imaging like MRI or CT, and cerebrospinal fluid or blood tests.

The process starts with your doctor asking detailed questions about your symptoms and medical history. Typical questions include asking about whether dementia runs in the family, how and when symptoms began, changes in behavior and personality, and if the person is taking certain medications that might cause or worsen symptoms.  There are various cognitive tests—like the infamous clock face drawing—that physicians can use to assess the likelihood of dementia.

Brain imaging can play a crucial role for some patients. Structural imaging with MRI or CT is primarily used to rule out other conditions that may cause symptoms similar to dementia but that require different treatment.  They can reveal tumors, evidence of strokes, damage from head trauma, or fluid buildup in the brain. Common MRI findings include brain atrophy, particularly shrinkage of the hippocampus which supports learning and memory and the cortex which supports perception, thought and voluntary action.  Other findings may include white matter changes that affect communication between brain regions.  Lesions from small strokes may be identified.

More sophisticated imaging like PET scans can detect specific proteins associated with Alzheimer’s. Recent advances in molecular imaging allow for visualization of amyloid and tau deposits in a living human brain, bringing us closer to an in vivo (while alive) definitive diagnosis.  This is significant because historically Alzheimer’s could only be definitively diagnosed at autopsy.

Treatment Options: Managing the Unmanageable

Here’s where I need to be honest: there’s no cure for dementia. But that doesn’t mean we’re helpless. Several medications can help manage symptoms and potentially slow progression.

For Alzheimer’s specifically, the FDA has approved two categories of drugs. These include drugs that change disease progression in people living with early Alzheimer’s disease, and drugs that may temporarily mitigate some symptoms. The newer disease-modifying drugs include donanemab and lecanemab.  They are anti-amyloid antibody intravenous infusion therapies that have demonstrated that removing beta-amyloid from the brain reduces cognitive and functional decline in people living with early Alzheimer’s.

More traditional treatments focus on symptom management. Medications such as galantamine, rivastigmine, and donepezil improve communication between nerve cells. Cholinesterase inhibitors work by preventing the breakdown of acetylcholine, a neurotransmitter, which may stabilize dementia symptoms.

Beyond medications, lifestyle modifications matter. Lifestyle changes including eating a balanced diet full of fruits and vegetables may help slow progression. Maintaining a routine to avoid confusion, including regular exercise and sleep, all help keep people with dementia as functional as possible for as long as possible.  Staying mentally active and socially connected can help slow the onset and progression of dementia.

What to Expect: The Prognosis

This is the hardest part to talk about.  The life expectancy of dementia patients varies enormously. Most people older than 65 with Alzheimer’s die within four to eight years of being diagnosed, but some people live for decades, especially if they were diagnosed before turning 65.

Life expectancy depends on a huge range of factors including the type of dementia diagnosed, overall health, and the age of diagnosis. Vascular dementia typically has a shorter life expectancy than Alzheimer’s disease due to underlying cardiovascular problems.

Progression happens in stages. Early symptoms include finding it hard to carry out familiar daily tasks, struggling to follow conversations or find the right word, and getting confused with familiar places. Signs of late-stage dementia include speaking in single words or repeated phrases that don’t make sense, not being able to understand what people are saying, or following things that are happening around them.

Those living with advanced dementia are especially prone to infection, constipation, skin ulcers and blood clots, which can put their life in danger if treatment is delayed.  Dehydration and malnutrition are serious risks for those without a strong support network as they often forget to eat or drink.  They are also more likely to be injured in falls and other accidents.

Ultimately, as you lose more brain function, activities vital to life begin to be affected, including breathing, swallowing, digestion, heart rate and sleep. Most people don’t die directly from dementia but from complications like pneumonia or falls.

A Note on Hope

Reading about dementia can feel depressing, but there’s reason for cautious optimism. While individual prognosis varies significantly and can’t be predicted with precision, early detection of symptoms and an early diagnosis can help with planning ahead to manage the disease.  Scientists continue researching new treatments, particularly regarding new biomarkers and disease modifying drugs.  Life expectancy estimates are improving all the time as many people are diagnosed earlier and receive better treatment and care. 

________________________________________________________________________

Sources

  1. National Institute on Aging – What Is Dementia? Symptoms, Types, and Diagnosis https://www.nia.nih.gov/health/alzheimers-and-dementia/what-dementia-symptoms-types-and-diagnosis
  2. NHS – Symptoms of Dementia https://www.nhs.uk/conditions/dementia/symptoms-and-diagnosis/symptoms/
  3. Cleveland Clinic – Dementia: What It Is, Causes, Symptoms, Treatment & Types https://my.clevelandclinic.org/health/diseases/9170-dementia
  4. CDC – About Dementia https://www.cdc.gov/alzheimers-dementia/about/index.html
  5. Cleveland Clinic – Alzheimer’s Disease: Symptoms & Treatment https://my.clevelandclinic.org/health/diseases/9164-alzheimers-disease
  6. Wikipedia – Dementia https://en.wikipedia.org/wiki/Dementia
  7. Practical Neurology – Brain Imaging in Differential Diagnosis of Dementia https://practicalneurology.com/diseases-diagnoses/imaging-testing/brain-imaging-in-differential-diagnosis-of-dementia/31533/
  8. Healthgrades – Vascular Dementia Life Expectancy: Statistics and Disease Progression https://resources.healthgrades.com/right-care/dementia/vascular-dementia-prognosis-and-life-expectancy
  9. Healthgrades – Dementia Life Expectancy: Stages and Progression https://resources.healthgrades.com/right-care/dementia/dementia-prognosis-and-life-expectancy
  10. Elder – Dementia and Life Expectancy: Planning for the Future https://www.elder.org/dementia-care/dementia-life-expectancy/
  11. Medical News Today – Dementia Life Expectancy: Duration and Stages https://www.medicalnewstoday.com/articles/how-long-does-dementia-last
  12. Alzheimer’s Association – Medications for Memory, Cognition & Dementia-Related Behaviors https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory
  13. Alzheimer’s Association – Medical Tests for Diagnosing Alzheimer’s & Dementia https://www.alz.org/alzheimers-dementia/diagnosis/medical_tests
  14. DRI Health Group – Can MRI Diagnose Dementia? https://drihealthgroup.com/health-tips/can-mri-diagnose-dementia

America’s Healthcare Paradox: Why We Pay Double and Get Less

By

On January 5, 2026

In Commentary, Medicine

The healthcare debate in America often circles back to a fundamental question: should we move toward a single-payer system, or is our current mixed public-private model the better path forward? It’s a conversation that gets heated quickly, but when you strip away the politics and look at how different systems actually function around the world, some interesting patterns emerge.

What We Mean by Single-Payer

A single-payer healthcare system means that one entity—usually the government or a government-related organization—pays for all covered healthcare services. Doctors and hospitals can still be private (and usually are), but instead of dealing with dozens of different insurance companies, they bill one source. It’s a lot like Medicare, which is why proponents often call it “Medicare-for-all”.

The key thing to understand is that single-payer isn’t necessarily the same as socialized medicine. In Canada’s system, for instance, the government pays the bills, but doctors are largely in the private sector and hospitals are controlled by private boards or regional health authorities rather than being part of the national government. Compare that to the UK’s National Health Service, where many hospitals and clinics are government-owned and many doctors are government employees.

America’s Current Patchwork

The United States operates what might charitably be called a “creative” approach to healthcare—a complex mix of employer-sponsored private insurance, government programs like Medicare, Medicaid and the VA system, individual marketplace plans, and direct out-of-pocket payments. Government already pays roughly half of total US health spending, but benefits, cost-sharing, and networks vary widely between plans, with little overall coordination.​ In 2023, private health insurance spending accounted for 30 percent of total national health expenditures, Medicare covered 21 percent, and Medicaid covered 18 percent.  Most of the remainder was either paid out of pocket by private citizens or was written off by providers as uncollectible.

Here’s where it gets expensive. U.S. health care spending grew 7.5 percent in 2023, reaching $4.9 trillion or $14,570 per person, accounting for 17.6 percent of the nation’s GDP, and national health spending for 2024 is expected to have exceeded $5.3 trillion or 18% of GDP, and health spending is expected to grow to 20.3 percent of GDP by 2033.

For a typical American family, the costs are real and rising. In 2024, the estimated cost of healthcare for a family of four in an employer-sponsored health plan was $32,066.

The European Landscape

Europe doesn’t have one healthcare model—it has several, and they’re all quite different from what we have in the States. Most of the 35 countries in the European Union have single-payer healthcare systems, but the details vary considerably.

Countries like the UK, Sweden, and Norway operate what are essentially single-payer systems where it is solely the government who pays for and provides healthcare services and directly owns most facilities and employs most clinical and related staff with funds from tax contributions. Then you have countries like Germany, and Belgium that use “sickness funds”—these are non-profit funds that don’t market, cherry pick patients, set premiums or rates paid to providers, determine benefits, earn profits or have investors. They’re quasi-public institutions, not private insurance companies like we know them in America.  Some systems, such as the Netherlands or Switzerland, rely on mandatory individually purchased private insurance with tight regulation and subsidies, achieving universal coverage with a structured, competitive market.

The French System

France is particularly noted for a successful universal, government-run health insurance system usually described as a single-payer with supplements. All legal residents are automatically covered through the national health insurance program, which is funded by payroll taxes and general taxation.

Most physicians and hospitals are private or nonprofit, not government employees or facilities. Patients generally have free choice of doctors and specialists, though coordinating through a primary care physician improves access and reimbursement. The national insurer pays a large portion of medical costs (often 70–80%), while voluntary private supplemental insurance covers most remaining out-of-pocket expenses such as copays and deductibles.

France is known for spending significantly less per capita than the United States. Cost controls come from nationally negotiated fee schedules and drug pricing rather than limits on access.

What’s striking is that in 2019, US healthcare spending reached $11,072 per person—over double the average of $5,505 across wealthy European nations. Yet despite spending roughly twice as much per person, American health outcomes often lag behind.

The Outcomes Question

This is where the comparison gets uncomfortable for American exceptionalism. The U.S. has the lowest life expectancy at birth among comparable wealthy nations, the highest death rates for avoidable or treatable conditions, and the highest maternal and infant mortality.

In 2023, life expectancy in comparable countries was 82.5 years, which is 4.1 years longer than in the U.S. Japan manages this with healthcare spending at just $5,300 per capita, while Americans spend more than double that amount.

Now, it’s important to note that healthcare systems don’t operate in a vacuum. Life expectancy is influenced by many factors beyond medical care—diet, exercise, smoking, gun violence, drug overdoses, and social determinants of health all play roles. But when you’re spending twice as much and getting worse results, it suggests the system itself might be part of the problem.

Advantages of Single-Payer Systems

The case for single-payer rests on several compelling points. First, administrative simplicity translates to real cost savings. A study found that the administrative burden of health care in the United States was 27 percent of all national health expenditures, with the excess administrative cost of the private insurer system estimated at about $471 billion in 2012 compared to a single-payer system like Canada’s. That’s over $1 out of every $5 of total healthcare spending just going to paperwork, billing disputes, and insurance company profit and overhead before any patient receives care.

Universal coverage is another major advantage. In a properly functioning single-payer system, nobody goes bankrupt from medical bills, nobody delays care because they can’t afford it, and nobody loses coverage when they lose their job. The peace of mind that comes with knowing you’re covered regardless of employment status or pre-existing conditions is difficult to quantify but enormously valuable.

Single-payer systems also have significant negotiating power. When one entity is buying drugs and services for an entire nation, pharmaceutical companies and medical device manufacturers have much less leverage to charge whatever they want. This helps explain why prescription drug prices in other countries are often a fraction of prices in the U.S.

Disadvantages and Trade-offs

The critics of single-payer systems aren’t wrong about everything. Wait times are a genuine concern in some systems. When prices and overall budgets are tightly controlled, some countries experience longer waits for selected elective surgeries, imaging, or specialty visits, especially if investment lags demand.

In 2024, Canadian patients experienced a median wait time of 30 weeks between specialty referral and first treatment, up from 27.2 weeks in 2023, with rural areas facing even longer delays. For procedures like elective orthopedic surgery, patients wait an average of 39 weeks in Canada.

However, it’s crucial to understand that wait times are not a result of the single-payer system itself but of system management, as wait times vary significantly across different single-payer and social insurance systems. Many European countries with universal coverage don’t experience the same wait time issues that plague Canada.

The transition costs are also substantial. Moving from our current system to single-payer would disrupt a massive industry. Over fifteen percent of our economy is related to health care, with half spent by the private sector. Around 160 million Americans currently have insurance through their employers, and transitioning all of them to a government-run plan would be an enormous administrative and political challenge.

A large national payer can be slower to change benefit designs or adopt new payment models; shifting political majorities can affect funding levels and benefit generosity.

Taxes would need to increase significantly to fund such a system, though proponents argue this would be offset by the elimination of insurance premiums, deductibles, and co-pays. It’s essentially a question of whether you’d rather pay through taxes or through premiums—the money has to come from somewhere.

Advantages of America’s Mixed System

Our current system does have some genuine strengths. Innovation thrives in the American healthcare market. The profit motive, for all its flaws, does drive pharmaceutical research and medical device development. American medical schools and research institutions lead the world in many areas of medicine.   Academic medical centers and specialty hospitals deliver advanced procedures and complex care that attract patients internationally.​

The system also offers more choice for those who can afford it. If you have good insurance, you typically face shorter wait times for elective procedures and can often see specialists without lengthy delays. Americans with high-quality employer-sponsored coverage give their plans relatively high ratings.

Competition between providers can theoretically drive quality improvements, though this effect is often undermined by the complexity of the market and the difficulty consumers face in shopping for healthcare.

Disadvantages of the Current U.S. System

The most glaring problem is simple: The United States remains the only developed country without universal healthcare, and 30 million Americans remain uninsured despite gains under the Affordable Care Act, and many of these gains will soon be lost. Being uninsured in America isn’t just an inconvenience—it can be deadly. People delay care, skip medications, and avoid preventive screenings because of cost concerns. 

The administrative complexity is staggering. Doctors spend enormous amounts of time dealing with insurance companies, prior authorizations, and billing disputes. Hospitals employ armies of billing specialists just to navigate the maze of different insurance plans, each with its own rules, formularies, and coverage determinations.  U.S. administrative costs account for ~25% of all healthcare spending, among the highest in the world.

Medical bankruptcy is uniquely American. Even people with insurance can find themselves financially devastated by serious illness. High deductibles, surprise bills, and out-of-network charges create a minefield of potential financial catastrophe.  Studies of U.S. bankruptcy filings over the past two decades have consistently found that medical bills and medical problems are a major factor in a large share of consumer bankruptcies. Recent summaries suggest that roughly two‑thirds of US personal bankruptcies involve medical expenses or illness-related income loss, and around 17% of adults with health care debt report declaring bankruptcy or losing a home because of that debt.

The system is also profoundly inequitable. Quality of care often depends more on your job, your income, and your zip code than on your medical needs. Out-of-pocket costs per capita have increased as compared to previous decades and the burden falls disproportionately on those least able to afford it.

What Europe Shows Us

The European experience demonstrates that there isn’t one “right” way to achieve universal coverage. The UK’s NHS, Germany’s sickness funds, and France’s hybrid system all manage to cover everyone at roughly half the per-capita cost of American healthcare. Universal Health Coverage exists in all European countries, with healthcare financing almost universally government managed, either directly through taxation or semi-directly through mandated and government-subsidized social health insurance.

They’ve accomplished this through various combinations of centralized negotiation of drug prices, global budgets for hospitals, strong primary care systems that serve as gatekeepers to more expensive specialist care, emphasis on preventive services, and regulation that prevents insurance companies from cherry-picking healthy patients.

Are these systems perfect? No. One of the major disadvantages of centralized healthcare systems is long wait lists to access non-urgent care, though Americans often wait as long or longer for routine primary care appointments as do patients in most universal-coverage countries. Many European countries are wrestling with funding challenges as populations age and expensive new treatments become available. But they’ve solved the fundamental problem that America hasn’t: they ensure everyone has access to healthcare without the risk of financial ruin.

The Path Forward?

The debate over healthcare in America often presents false choices. We don’t have to choose between Canadian-style single-payer and our current system—there are multiple models we could adapt. We could move toward a German-style system with heavily regulated non-profit insurers. We could create a robust public option that competes with private insurance. We could expand Medicare gradually by lowering the eligibility age over time.

What’s clear from international comparisons is that the status quo is unusually expensive and produces mediocre results. We’re paying premium prices for economy outcomes. Whether single-payer is the answer depends partly on your priorities. Do you value universal coverage and cost control more than unlimited choice? Are you willing to accept potentially longer wait times for non-urgent care in exchange for lower costs and universal access? How much do you trust government to manage a program this large?

These aren’t easy questions, and reasonable people disagree. But the evidence from Europe suggests that universal coverage at reasonable cost is achievable—it just requires us to make some choices about what we value most in a healthcare system.

Sources:

The Multitasking Myth

By

On December 20, 2025

In Commentary, Medicine

What’s Really Happening in Your Brain

You’re probably multitasking right now. Maybe you’re reading this with a podcast playing in the background, or you’ve got three browser tabs open and you’re checking your phone every few minutes. We all do it. We even brag about it on resumes: “Excellent multitasker!” But here’s the uncomfortable truth that neuroscience has been trying to tell us for years—what we call multitasking is mostly an illusion.

What People Actually Mean

When most people say they’re multitasking, they’re describing one of two scenarios. The first is doing multiple automatic activities simultaneously—like walking while talking, or listening to music while folding laundry. The second, and the one that gets more interesting, is rapidly switching attention between different demanding tasks—like answering emails while on a conference call, or texting while watching TV.

The distinction matters because our brains handle these situations very differently. Activities that have become automatic through practice don’t require much conscious attention. You can absolutely walk and chew gum at the same time because neither activity demands your prefrontal cortex’s full attention. But when both tasks require active thinking and decision-making? That’s where things get complicated.

The Brain’s Bottleneck

Here’s what neuroscience tells us: true multitasking—simultaneously processing multiple streams of complex information—is essentially impossible for the human brain. What feels like multitasking is actually rapid task-switching, and your brain pays a price every time it makes that switch.

The limitation comes from something researchers call the “response selection bottleneck.” When you’re performing tasks that require conscious thought, they all funnel through the same neural pathways in your prefrontal cortex. This region can only process one demanding task at a time, so when you think you’re doing two things at once, you’re really just toggling between them very quickly.

Studies using functional MRI brain imaging have shown what happens during this switching process. When people attempt to multitask, researchers observe reduced activity in the regions responsible for each individual task compared to when those tasks are done separately. Your brain literally can’t devote full processing power to both activities simultaneously.

The Switching Cost

Every time you switch from one task to another, there’s a cognitive cost. Your brain needs to disengage from the first task, shift attention, and then reorient to the new task. This happens so quickly—sometimes in tenths of a second—that we don’t consciously notice it. But those microseconds add up.

Sorry, but get ready for some doctor talk.  When people switch tasks, imaging studies show increased activation in frontoparietal control and dorsal attention networks, especially in prefrontal regions (like the inferior frontal junction) and parietal cortex (such as intraparietal sulcus). This boosted activity reflects the brain dropping one task set, loading another into working memory, and re‑orienting attention—processes that consume time and neural resources.

Over time, practice can make specific tasks more automatic, reducing average activity in these control networks and allowing smoother coordination of tasks. However, even in trained multitaskers, studies still find evidence for serial queuing of operations in the multiple‑demand frontoparietal network, reinforcing the idea that consciously doing multiple demanding things “at once” is extremely limited.

Research from Stanford University found that people who regularly engage in heavy media multitasking actually perform worse at filtering out irrelevant information and switching between tasks than people who focus on one thing at a time. Essentially, chronic multitaskers become worse at the very thing they practice most.

Even when people train extensively, studies indicate they mainly become faster at switching and coordinating, not truly doing two demanding tasks at once. Experimental work using reaction‑time paradigms shows a reliable “switch cost”: when people change tasks, responses get slower and more error‑prone compared to staying with one task.  This cost is one of the strongest signs that most human “multitasking” is serial switching under time pressure rather than genuine simultaneous processing.

The American Psychological Association reports that these mental blocks created by switching between tasks can cost up to 40% of productive time. Think about that for a minute—nearly half your work time potentially lost to the mechanics of jumping between activities.

The Attention Residue Problem

There’s another wrinkle that makes multitasking even less efficient. When you switch away from a task before completing it, part of your attention remains stuck on the unfinished work. Researchers call this “attention residue,” and it reduces your cognitive performance on the next task.

Sophie Leroy, a business professor at the University of Washington, demonstrated this effect in a series of studies. People who switched tasks performed significantly worse on the second task than people who finished the first task before moving on. The unfinished task keeps running in your mental background, using up cognitive resources you need for the new activity.

When “Multitasking” Actually Works

There are legitimate exceptions to the no-multitasking rule, but they’re more limited than most people think. You can successfully combine activities when at least one of them is so well-practiced that it’s become automatic—essentially requiring no conscious thought. You can listen to an audiobook while jogging because your body handles the running on autopilot.

Some research also suggests that certain types of background music or ambient noise can enhance performance on creative tasks, though this seems to work best when the music is familiar and lacks lyrics that compete with language-processing tasks.

Why We Keep Trying

If multitasking is so inefficient, why do we persist? Part of the answer lies in how it feels. Task-switching triggers the release of dopamine, the brain’s reward chemical. Every time you check your phone or switch to a new browser tab, you get a little neurochemical hit. It feels productive, even when it isn’t.

There’s also a cultural element. We live in an attention economy where being constantly connected and responsive feels mandatory. Focusing on one thing can feel like you’re missing out or falling behind, even though the research consistently shows that single-tasking produces better results faster.

It’s worth noting that research consistently shows this gap between perception and performance.  People who think they are excellent multitaskers tend to be the worst at it.

The Bottom Line

The evidence is pretty clear: what we call multitasking is really task-switching, and it makes us slower and more error-prone at both activities. Your brain has a fundamental processing limitation that hasn’t changed despite our increasingly multi-screen world. The prefrontal cortex can only fully engage with one complex task at a time, and switching between tasks creates cognitive costs that add up to significant lost productivity and increased mistakes.

This doesn’t mean you should never listen to music while working or that walking while talking will melt your brain. But when you’re doing something that really matters—writing an important email, having a meaningful conversation, learning something new—giving it your full attention will always produce better results than splitting your focus.

A1c Without Diabetes: Context Matters As Much As The Number

By

On December 17, 2025

In Medicine

If you’ve had routine bloodwork lately, you might have noticed something called hemoglobin A1c (or HbA1c) on your results. For years, this test has been the gold standard for monitoring diabetes, but it’s increasingly also  being used to assess metabolic health in people who don’t have diabetes. Let’s dig into what this number actually tells us and if lower is always better.

What A1c Actually Measures

Hemoglobin A1c reflects your average blood sugar levels over the past two to three months. When glucose circulates in your bloodstream, some of it sticks to hemoglobin—the oxygen-carrying protein in your red blood cells. The more glucose floating around, the more hemoglobin gets “glycated” (coated with sugar). Since red blood cells live about three months, your A1c percentage gives a rolling average of your blood sugar control. It does not capture individual spikes and dips in glucose, but it correlates reasonably well with overall glycemic exposure and is widely used to monitor diabetes control.

For non-diabetics, a normal A1c is generally considered below 5.7%. The prediabetes range sits between 5.7% and 6.4%, while 6.5% or higher on two separate tests typically indicates diabetes.  Nondiabetic adults with A1c above about 6% are more likely to have impaired fasting glucose and other cardiometabolic risk factors than those with A1c around 5.2–5.3%.​

These cutoffs represent points where research has shown increased risk for complications, but like most biological measurements, they exist on a spectrum rather than as hard dividing lines. 

Even in non-diabetics, A1c can vary by genetics, age, ethnicity, iron levels, sleep quality, and stress—not just diet or exercise. That’s why one person may live at 5.2% with no effort, while another naturally runs 5.6%.

The Prediabetes Gray Zone

Here’s where things get interesting—and a bit complicated. Prediabetes affects roughly 98 million American adults, though most don’t know they have it. An A1c between 5.7% and 6.4% signals that your body’s relationship with glucose isn’t quite right. Maybe your cells are becoming resistant to insulin, or your pancreas isn’t producing insulin as efficiently as it once did.  Prediabetes isn’t a disease so much as a metabolic warning sign. It means your body is starting to struggle with glucose regulation—often due to reduced insulin sensitivity, higher visceral fat, chronic stress, poor sleep, or genetics.

The crucial thing about prediabetes is that it’s not a benign waiting room before diabetes. Research shows that even in this intermediate range, you face elevated risks for cardiovascular disease, kidney problems, and nerve damage—though not to the same degree as someone with full-blown diabetes. It often coexists with other metabolic risk factors such as excess weight, dyslipidemia, and elevated blood pressure.​ A large study published in The Lancet found that people with A1c levels in the prediabetic range had a 15-20% increased risk of cardiovascular events compared to those with normal levels.

The good news? Prediabetes is often reversible. Lifestyle changes—particularly losing 5-7% of body weight through diet and exercise—can bring A1c levels back down. The Diabetes Prevention Program, a landmark study, showed that such interventions reduced the risk of developing diabetes by 58% over three years.

Should Non-Diabetics Aim Lower?

Now we arrive at the million-dollar question: if your A1c is already in the normal range (say, 5.3%), would driving it even lower—to 5.0% or 4.8%—provide additional health benefits?

The honest answer is: we don’t really know, but the evidence suggests probably not much.

Here’s what the research tells us. Population studies have found a continuous relationship between A1c levels and cardiovascular risk even within the normal range, meaning that someone with an A1c of 5.5% might have slightly higher risk than someone at 5.0%. However—and this is critical—this doesn’t necessarily mean that artificially lowering your A1c will reduce that risk. Correlation isn’t causation.

Your A1c reflects your overall metabolic health, dietary patterns, genetics, and lifestyle. Someone who naturally maintains an A1c of 5.0% because they exercise regularly, eat a balanced diet, and have favorable genetics probably has lower risk than someone at 5.5%. But that doesn’t mean the person at 5.5% should obsess over shaving off half a percentage point.  Large cohort data suggest that the lowest risk band for nondiabetic adults is roughly an A1c around 5.0–5.6%; below about 5.0% the relationship between A1c and outcomes becomes more complex.

There’s a principle in medicine that “lower is better”  but it often has limits. In diabetes treatment, pushing A1c too low can actually increase risks—particularly hypoglycemia (dangerously low blood sugar), which carries its own serious complications. The ACCORD trial, which studied intensive glucose lowering in people with Type 2 diabetes, had to be stopped early because the group targeting very low A1c levels had increased mortality. While this study involved diabetics using medications, it illustrates that extremely low glucose isn’t necessarily optimal.

If someone tries to force their A1c unusually low through extreme dieting, fasting, or intensive exercise, they can run into unintended effects such as fatigue and irritability, hormonal disruption, disordered eating patterns, and nutrient deficiencies.  Importantly, extremely low A1c values can sometimes reflect anemia or other medical conditions, not superior health.

For non-diabetics with normal A1c levels, there’s no evidence that trying to push numbers lower through extreme dietary restriction or other interventions provides meaningful benefit. Your body is already handling glucose appropriately. The focus should be on maintaining that healthy state through sustainable lifestyle habits rather than chasing incremental improvements in a single biomarker. In practical terms, the benefit is less about the exact number (say 5.1 versus 4.8) and more about maintaining a metabolic profile that keeps A1c comfortably below the prediabetes threshold over the long term

What Actually Matters

Rather than fixating on squeezing every tenth of a point out of your A1c, the evidence supports a broader approach to metabolic health. Regular physical activity, maintaining a healthy weight, eating a diet rich in whole foods with plenty of fiber, getting adequate sleep, and managing stress all contribute to healthy glucose metabolism—and they bring countless other benefits beyond A1c.

It’s also worth noting that A1c isn’t perfect. Certain conditions—like anemia, chronic kidney disease, or hemoglobin variants—can make A1c readings inaccurate. Some people have A1c levels that don’t match what their continuous glucose monitors show, a phenomenon called “glycation gap.” A1c is a useful tool, but it’s one piece of a larger metabolic picture.

The bottom line? If your A1c is in the normal range, you’re doing well. Maintain the healthy habits that got you there rather than micromanaging the number itself. If you’re in the prediabetic range, you have a genuine opportunity to prevent diabetes through lifestyle changes, and bringing that number down has clear benefits. But for those already in the healthy zone, obsessing over fractional improvements likely won’t move the needle much on your actual health outcomes.

Understanding Parkinson’s Disease: From Diagnosis to Daily Living

By

On December 13, 2025

In Medicine, Uncategorized

When most people think of Parkinson’s disease, they picture the characteristic tremor—that involuntary shaking that has become almost synonymous with the condition. But the reality is far more complex than just one visible symptom. Let’s dig into what’s actually happening in the brain, how doctors figure out what’s going on, and what living with this condition really looks like.

What Causes Parkinson’s Disease?

Here’s where things get frustrating for researchers: despite decades of study, scientists still don’t know exactly what causes the nerve cells in the brain to die. I’m going to apologize in advance because I’m going to be using a lot of “doctor talk”—no way around it. 

What we do know is that nerve cells (neurons) in the substantia nigra portion of the basal ganglia—an area of the brain controlling movement—become impaired or die, and these neurons normally produce dopamine, an important brain chemical. When these cells stop working properly, dopamine levels drop, and that’s when movement problems begin showing up.

But dopamine isn’t the whole story. People with Parkinson’s also lose nerve endings that produce norepinephrine, the main chemical messenger of the sympathetic nervous system, which helps explain why the disease affects so much more than just movement—things like blood pressure, digestion, and energy levels all take a hit.

Most Parkinson’s cases are idiopathic, meaning the cause is unknown, though contributing factors have been identified. Current thinking suggests a complicated mix of genetic and environmental factors. About 5% to 10% of cases begin before age 50, and these early-onset forms are often, though not always, inherited.

Some risk factors have emerged from research: age is the most significant, with about 1% of those over 65 and around 4.3% of those over 85 affected. Traumatic brain injury significantly increases risk, especially if recent, and repeated head injuries from contact sports can cause what’s called post-traumatic parkinsonism.  Muhammad Ali is a classic example of this.

Exposure to pesticides and industrial chemicals has also been identified as a risk factor.  Interestingly, large epidemiologic studies consistently show that people who smoke have a lower risk of being diagnosed with Parkinson’s disease than never‑smokers, although smoking is still strongly discouraged because of its many harmful health risks.  Large cohort studies in the U.S. and Europe generally find no direct association between alcohol consumption and Parkinson’s disease. A few observational studies show that moderate drinkers have slightly lower Parkinson’s rates. However, researchers believe this may be due to reverse causation (people in early or undiagnosed stages often reduce drinking because of GI or mood changes) and lifestyle confounders (moderate drinkers may differ in socioeconomic status, diet, or activity level).  So, the “protective” effect is considered speculative, not causal.  

The Symptoms: More Than Just Shaking

The hallmark movement symptoms—what doctors call “motor symptoms”—are what usually bring people to the doctor. Slowed movements, called bradykinesia, is required for a Parkinson’s diagnosis. People describe it as muscle weakness, though it’s really about control, not strength. The classic tremor, stiffness, and balance problems round out the main movement issues.  Patients frequently show reduced arm swing, shuffling gait, difficulty initiating movement or turning, masked facial expression, decreased blinking, and soft or monotone speech.

But here’s what often surprises people: many individuals later diagnosed with Parkinson’s notice that prior to experiencing stiffness and tremor, they had sleep problems, constipation, loss of smell, and restless legs. These “prodromal symptoms” can show up years before the movement problems become obvious. Other early signs include mood disorders like anxiety and depression.

The cognitive side deserves attention too. Some people experience changes in cognitive function, including problems with memory, attention, and the ability to plan and accomplish tasks, though hard to pin down due to concurrence with age related memory problems, 20% at the time of diagnosis is a commonly cited number.  More contested is how many develop Parkinson’s dementia, with estimates ranging from 20% all the way to 85%.

How Doctors Make the Diagnosis

Here’s something that might surprise you: there are currently no blood or laboratory tests to diagnose non-genetic cases of Parkinson’s. The standard diagnosis is clinical, meaning there’s no test that can give a conclusive result—certain physical symptoms need to be present.

Doctors typically diagnose Parkinson’s by taking a detailed medical history and performing a neurological examination. If symptoms improve after starting medication, that’s another indicator that the person has Parkinson’s.

There are some imaging tools available. The FDA approved an imaging scan called the DaTscan in 2011, which allows doctors to see detailed pictures of the brain’s dopamine system using a radioactive drug and SPECT scanner. But this scan can’t definitively diagnose Parkinson’s though it helps rule out conditions that mimic it.  A hallmark of Parkinson’s is the buildup of misfolded alpha-synuclein proteins (Lewy bodies) inside neurons. Whether this is a cause, an effect, or both is still under study—this part of the science remains somewhat speculative.

Recently, researchers developed something more promising: the alpha-synuclein seeding amplification assay can detect abnormal alpha-synuclein in spinal fluid and may detect Parkinson’s in people who haven’t been diagnosed yet. The catch? It requires a spinal tap and isn’t widely available, though scientists are working on blood and saliva tests.

The early diagnostic challenge is real. Many disorders can cause similar symptoms, and people with Parkinson’s-like symptoms from other causes are sometimes said to have parkinsonism, which includes conditions like multiple system atrophy and Lewy body dementia that require different treatments.

What to Expect: The Prognosis

Let’s address the big question: how does Parkinson’s affect life expectancy? The news here is better than you might think. The average life expectancy of a person with Parkinson’s is generally the same as for someone without the disease.

More specifically, average life expectancy has increased by about 55% since 1967, rising to more than 14.5 years from diagnosis. Modern treatments have made a huge difference. Research indicates that those with Parkinson’s and normal cognitive function appear to have a largely normal life expectancy.

That said, timing matters. Research from 2020 suggests that people who receive a diagnosis before age 70 usually experience a greater reduction in life expectancy, and males with Parkinson’s may have a greater reduction in life expectancy than females.

The disease is progressive, meaning it gets worse over time, but symptoms and progression vary from person to person, and neither you nor your doctor can predict which symptoms you’ll get, when, or how severe they’ll be. The tremor-dominant type usually has a more favorable prognosis than the hypokinetic type.

What actually causes death in advanced Parkinson’s? Advanced symptoms can cause falls, pressure ulcers, swallowing difficulties and general frailty, all of which are linked to death. Aspiration pneumonia—when you inhale food or liquid into the lungs—is the leading cause of death for people with Parkinson’s.

Managing the Disease

Currently, there’s no cure for Parkinson’s, but medications or surgery can improve many of the movement symptoms.

The gold standard medication is levodopa (often combined with carbidopa as Sinemet). Healthcare providers use levodopa cautiously and they commonly combine it with other medications to keep your body from processing it before it enters your brain.  This helps avoid side effects like nausea, vomiting, and low blood pressure when standing up. The tricky part? Over time, the way your body uses levodopa changes, and it can lose effectiveness.

Beyond levodopa, doctors use MAO-B inhibitors and dopamine agonists. As the disease progresses, these medications become less effective and may cause involuntary muscle movements. When drugs stop working well, there are surgical options to treat severe motor symptoms.

The main surgical treatment today is called deep brain stimulation (DBS).  It is the most important therapeutic advancement since the development of levodopa, and it’s been FDA-approved since the late 1990s A surgeon places thin metal wires called electrodes into one or both sides of the brain, in specific areas that control movement. A second procedure implants an impulse generator battery under the collarbone or in the abdomen. It is similar to a heart pacemaker and about the size of a stopwatch, this device delivers electrical stimulation to those targeted brain areas.

A new treatment that is being used is focused ultrasound. Guided by MRI, high-intensity, inaudible sound waves are emitted into the brain, and where these waves cross, they create high energy that destroys a very specific area connected to tremor. It’s considered non-invasive and the FDA has approved it for Parkinson’s tremor that doesn’t respond to medications.

Don’t underestimate lifestyle interventions either. Physical therapy can improve balance and address muscle stiffness, and regular exercise improves strength, flexibility, and balance. Eating a balanced diet helps—drinking plenty of water and eating enough fiber reduces constipation, while omega-3 fats and magnesium may boost cognition and help with anxiety.

Parkinson’s disease sits at the intersection of aging, genetics, environment, and biology. Diagnosis is clinical, progression is gradual and variable, and treatment has become increasingly sophisticated. While it remains incurable, early diagnosis, personalized medication plans, targeted therapies like DBS, and consistent exercise allow many people to maintain meaningful independence for years.

The key message from specialists? Treatment makes a major difference in keeping symptoms from having worse effects, and adjustments to medications and dosages can hugely impact how Parkinson’s affects your life.

The Correlation Mirage: How Good Intentions Go Wrong in Health Debates

By

On December 8, 2025

In Commentary, Medicine

Understanding the Basics

Here’s the fundamental problem: just because two things happen together doesn’t mean one caused the other. When we say two variables are “correlated,” we’re simply observing that they move in tandem—when one goes up, the other tends to go up (or down). Causation, on the other hand, means that a change in one variable directly causes a change in the other. Think of correlation as a suspicious coincidence, while causation is a proven relationship with a clear mechanism.

The tricky part is that our brains are pattern-seeking machines. We evolved to spot connections quickly because that helped our ancestors survive. If you ate those red berries and got sick, better to assume the berries caused it rather than to wait around for a controlled study. But this mental shortcut can seriously mislead us in the modern world, especially when it comes to complex health issues.

Classic Examples That Illustrate the Problem

Let me give you some examples that show how ridiculous this confusion can get when we’re not careful. There’s a famous correlation between ice cream sales and drowning—both increase during summer months, but ice cream isn’t causing drowning. The real driver is warmer weather, which leads people to both buy more ice cream and to spend more time at beaches or swimming pools where drowning might happen. This is what researchers call a “confounding variable”—a third factor that influences both things you’re measuring.

Here’s another head-scratcher: there’s a correlation between the number of master’s degrees awarded and box office revenue. Does getting more education somehow boost movie sales? Of course not. This is what we call a spurious correlation—a completely coincidental relationship that exists in the data but has no meaningful connection in reality.

Here’s good news for us coffee drinkers.  For years, studies suggested a correlation between heavy coffee drinking and heart disease. Later research found the real issue: heavy coffee drinkers were also more likely to smoke. Once smoking was controlled for, coffee itself did not increase heart risk.

Perhaps the most amusing example is the correlation between stork populations and birth rates in Germany and Denmark spanning decades. As the stork population fluctuated, so did the number of newborns. Now, you could construct a “Theory of the Stork” claiming that storks deliver babies, but the real explanation probably involves other variables like weather patterns, urbanization, or environmental developments that affected both populations.

The medical field offers more serious examples. You observe a strong correlation between exercise and skin cancer cases—people who exercise more seem to get skin cancer at higher rates. Without digging deeper, you might panic and conclude that exercise somehow causes cancer. But the actual explanation is far more mundane: people who exercise more tend to spend more time outdoors in the sun, which increases their UV exposure. The confounding variable here is sun exposure, not the exercise itself.

The Vaccine-Autism Controversy: A Cautionary Tale

Now let’s talk about one of the most damaging correlation-causation confusions in recent medical history: the claim that vaccines cause autism. Many childhood vaccines are administered at the same ages when numerous developmental conditions first become noticeable—including autism, seizure disorders, and certain metabolic or genetic issues.  This is a textbook case of how mistaking correlation for causation can have real-world consequences.

The whole mess started in 1998 when Andrew Wakefield, a gastroenterologist at London’s Royal Free Hospital, published a paper in The Lancet describing 12 children, eight of whom were reported as having developed autism after receiving the MMR vaccine. Here’s the thing: this wasn’t even a proper study that could establish causation. It was described as a consecutive case series with no control group or control period—it was simply a description that couldn’t tell you whether one thing causes another.

But why did this idea catch fire so dramatically? The timing created a perfect storm for correlation-causation confusion. Autism becomes apparent early in childhood, around the same time children receive many vaccines and there will be a temporal relationship by chance alone. Parents naturally searched for explanations, noticed the temporal proximity, and drew what seemed like an obvious conclusion.

The scientific community took these concerns seriously and conducted extensive research. Despite overwhelming data demonstrating that there is no link between vaccines and autism, many parents remain hesitant to immunize their children because of the alleged association. Study after study found no connection. A study of over 500,000 children in Denmark, published in The New England Journal of Medicine in 2002 found no relationship between autism and MMR as did a subsequent Danish study published in 2019.  In April 2015, JAMA published a large study analyzing health records of over 95,000 children, including about 2,000 who were at risk for autism because they had a sibling already diagnosed.  It confirmed that the MMR vaccine did not increase the risk for autism spectrum disorder.

The original Wakefield study eventually collapsed under scrutiny. The Lancet retracted the article, and Wakefield was found guilty of deliberate fraud—he picked and chose data that suited his case and falsified facts. Wakefield lost his license to practice medicine after being sanctioned by scientific bodies. But by then, the damage was done.

Here’s the correlation-causation issue in stark terms: the prevalence of autism has increased over time, which researchers and healthcare professionals explain is likely due to multiple factors, including people becoming more aware of autism, improved screening, and updated and expanded diagnostic criteria to include other conditions on the autism spectrum. Meanwhile, immunizations have increased and have dramatically reduced the incidence of vaccine-preventable diseases. These two trends—increasing autism diagnoses and increasing vaccination rates—happened to occur during the same historical period, creating an illusory correlation.

The real causes of autism are complex. There is no single root cause; a combination of influences is likely involved, including certain genetic syndromes, genetic changes affecting cell function, and environmental influences such as premature birth, older parents, and illness during pregnancy. Vaccines simply aren’t part of that picture.

Other Health-Related Confusion

The vaccine-autism controversy isn’t the only place where correlation-causation confusion causes problems in health contexts. Let me give you a few more examples that show how pervasive this issue is and how difficult it can be to distinguish between correlation and causation. 

Consider the relationship between diet and health outcomes. The amount of sodium a person gets in their diet is closely correlated to the total calories they eat—in other words, the more a person eats, the more sodium they’re likely to take in, and eating a lot of calories often leads to obesity. Both obesity and high-sodium diets are believed to contribute to high blood pressure. So, what’s the primary driver? Is it sodium, excess calories, or obesity? These are exactly the kinds of questions researchers must carefully untangle.

Here’s another tricky one: research has shown a correlation between antibiotic use in children and increased risk of obesity, with greater antibiotic use associated with higher obesity risk, particularly for children with four or more exposures. But this correlation alone doesn’t tell us whether antibiotics cause obesity. There could be multiple explanations: perhaps children who need frequent antibiotics have other health issues that predispose them to weight gain, or perhaps the infections themselves (not the antibiotics) are the real issue, or maybe it’s actually a disruption of gut bacteria that matters. Without understanding the exact physiological mechanism, we can’t design effective interventions.

Similarly, increased BMI seems to be associated with an increased risk of several cancers in adults. But it would be erroneous to conclude that simply being overweight directly causes cancer. Socioeconomic factors, environmental toxins, access to healthcare, lifestyle differences, physical activity levels, and diet all intertwine in complex ways. Some people may face multiple risk factors simultaneously, making it difficult to isolate which factors are most significant.

When cell phones first became widely used, there was an increasing concern that radiation from the cell phones was causing brain cancer. Brain cancer rates have remained stable for decades despite exponential increases in cell-phone use—strong evidence against a causal relationship.

Beyond Statistics

The stakes here go way beyond academic accuracy. When people confuse correlation with causation in health contexts, they make decisions that can harm themselves and others. The 2017 measles epidemic in Minnesota’s Somali community was in no small measure fomented by Wakefield—he didn’t fade away quietly. He and other anti-vaxers repeatedly proselytized to the community, leading to an approximately 45% reduction in vaccination. At the same time there was an increase in autism diagnoses. Think about that: vaccination rates dropped, yet autism diagnoses continued to rise—the exact opposite of what you’d expect if vaccines caused autism.  A word of caution: this is an observation, not a carefully controlled study.

The problem extends to how we evaluate new treatments and risk factors. In clinical medicine, there are treatment protocols in use that are not supported by randomized controlled trials. There are risk factors that have been associated with various diseases where it’s difficult to know for certain if they are actually contributing causes. This uncertainty creates space for misunderstanding.

How Scientists Establish Causation

So, how do researchers move from observing a correlation to proving causation? They look for several key elements. These include: a stronger association between variables (which is more suggestive of cause and effect than a weaker one), proper temporality (the alleged effect must follow the suspected cause), a dose-response relationship (where increasing exposure leads to proportionally greater effects), and a biologically plausible mechanism of action.

The gold standard is the randomized controlled trial, where researchers can carefully control for confounding variables by randomly assigning people to treatment and control groups. For ethical reasons, there are limits to controlled studies—it wouldn’t be appropriate to use two comparable groups and have one undergo a harmful activity while the other does not. That’s why we often rely on observational studies combined with careful statistical methods to rule out alternative explanations.

The Bottom Line

Understanding the difference between correlation and causation isn’t just an academic exercise—it’s a critical thinking skill that helps you navigate health claims, news stories, and medical decisions. The vaccine-autism controversy shows how dangerous it can be when we mistake coincidental timing for causal relationships, especially when those misunderstandings spread through communities and lead to preventable disease outbreaks.

The key takeaway? When you see two things happening together, your brain will want to assume one caused the other. Resist that urge. Ask yourself: could there be a third factor driving both? Could the timing just be coincidental? Is there a clear, testable mechanism that would explain how one causes the other? These questions can help you separate meaningful connections from statistical coincidences—and potentially save you from making poor health decisions based on faulty reasoning.

Page 2 of 7

Previous

Next

Powered by WordPress & Theme by Anders Norén